The stock of Radius Health Inc (NASDAQ:RDUS) is a huge mover today! About 707,975 shares traded hands. Radius Health Inc (NASDAQ:RDUS) has risen 45.02% since March 9, 2016 and is uptrending. It has outperformed by 37.61% the S&P500.
The move comes after 9 months negative chart setup for the $2.33 billion company. It was reported on Oct, 12 by Barchart.com. We have $49.82 PT which if reached, will make NASDAQ:RDUS worth $116.50M less.
Analysts await Radius Health Inc (NASDAQ:RDUS) to report earnings on November, 3. They expect $-1.04 earnings per share, down 52.94% or $0.36 from last year’s $-0.68 per share. After $-1.01 actual earnings per share reported by Radius Health Inc for the previous quarter, Wall Street now forecasts 2.97% negative EPS growth.
Radius Health Inc (NASDAQ:RDUS) Ratings Coverage
Out of 9 analysts covering Radius Health (NASDAQ:RDUS), 7 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 78% are positive. Radius Health has been the topic of 13 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The stock has “Overweight” rating given by JP Morgan on Friday, October 2. The stock of Radius Health Inc (NASDAQ:RDUS) earned “Buy” rating by H.C. Wainwright on Monday, May 23. The stock of Radius Health Inc (NASDAQ:RDUS) has “Hold” rating given on Wednesday, February 24 by Jefferies. On Wednesday, September 21 the stock rating was maintained by H.C. Wainwright with “Buy”. Canaccord Genuity maintained Radius Health Inc (NASDAQ:RDUS) rating on Thursday, September 24. Canaccord Genuity has “Buy” rating and $85.0 price target. Goldman Sachs initiated the stock with “Neutral” rating in Wednesday, March 30 report. Cowen & Co reinitiated the shares of RDUS in a report on Friday, May 6 with “Outperform” rating. The stock of Radius Health Inc (NASDAQ:RDUS) has “Buy” rating given on Friday, August 14 by Deutsche Bank.
According to Zacks Investment Research, “Radius Health Inc. is a science-driven biopharmaceutical company. It is focused on developing novel differentiated therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases. The Company’s lead product candidate, abaloparatide (BA058), is in development, in both injection (Abaloparatide-SC) and transdermal (Abaloparatide-TD) methods of administration, for the prevention of fractures in post-menopausal women at risk of fracture from osteoporosis. Radius Health Inc. is based in Cambridge, Massachusetts.”
Insitutional Activity: The institutional sentiment increased to 1.32 in Q2 2016. Its up 0.03, from 1.29 in 2016Q1. The ratio improved, as 20 funds sold all Radius Health Inc shares owned while 33 reduced positions. 22 funds bought stakes while 48 increased positions. They now own 42.68 million shares or 5.94% more from 40.29 million shares in 2016Q1.
The California-based Blackrock Fund has invested 0.01% in Radius Health Inc (NASDAQ:RDUS). Blackrock Institutional Trust Co Na holds 792,644 shares or 0% of its portfolio. Wealthtrust holds 350 shares or 0.01% of its portfolio. Lord Abbett & Ltd Liability Co holds 0.01% or 65,604 shares in its portfolio. Gru One Trading Ltd Partnership has invested 0.03% of its portfolio in Radius Health Inc (NASDAQ:RDUS). Proshare Advsr Lc has invested 0.02% of its portfolio in Radius Health Inc (NASDAQ:RDUS). Fifth Third Retail Bank holds 3,421 shares or 0% of its portfolio. Millennium Mngmt Ltd Liability Co has 99,319 shares for 0.01% of their US portfolio. Jefferies Gru Limited Liability Co has 2,140 shares for 0% of their US portfolio. Bank & Trust Of America De last reported 0% of its portfolio in the stock. The Missouri-based American Century Companies has invested 0% in Radius Health Inc (NASDAQ:RDUS). Us Savings Bank De holds 1,818 shares or 0% of its portfolio. Cowen Group Inc Incorporated last reported 6,500 shares in the company. Sei, a Pennsylvania-based fund reported 1,768 shares. Deutsche Bank & Trust Ag accumulated 0.02% or 775,163 shares.
More recent Radius Health Inc (NASDAQ:RDUS) news were published by: Fool.com which released: “Why Radius Health Inc. Dropped 45% in January” on February 08, 2016. Also Fool.com published the news titled: “Why Radius Health Inc. is Screaming Higher Today” on February 22, 2016. Philly.com‘s news article titled: “Radius Health eyes drug launch, expands in Wayne” with publication date: June 22, 2016 was also an interesting one.
RDUS Company Profile
Radius Health, Inc. is a biopharmaceutical firm focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis. The Company’s clinical pipeline also includes an investigational abaloparatide transdermal patch for use in osteoporosis and the investigational drug RAD1901 for use in hormone-driven and hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. The Company’s preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for use in cancer.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.